Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00991692 · ClinicalTrials.gov registry record · NA

A Multisite Trial of ACQUIREc Therapy

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
18
Enrollment target

NCT00991692 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00991692, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
18 participants
Enrollment target

Study Summary

A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy services for 21 days. It was hypothesized that children receiving the higher therapy dosage would have greater and more clinically significant benefits from ACQUIREc Therapy but that both groups of children would benefit from the therapy services.

Interventions

  • OTHER Therapy services (ACQUIREc Therapy)

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2008-06
Est. Completion 2009-10
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT00991692

The ClinicalTrials.gov registry entry for NCT00991692 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Therapy services (ACQUIREc Therapy) is the first listed.

NCT00991692 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00991692 about?

NCT00991692 is a clinical study titled "A Multisite Trial of ACQUIREc Therapy". A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy s...

What is the current status of trial NCT00991692?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2008-06. Estimated completion is 2009-10.

What interventions are being tested in trial NCT00991692?

The interventions under investigation include: Therapy services (ACQUIREc Therapy) (OTHER).

Who is sponsoring clinical trial NCT00991692?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.